Back to News
Apr 7, 2026 4:00 PM

Why Is Telix Pharma Stock Soaring Tuesday?

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares climbed Tuesday after the company reported solid revenue growth and continued progress across its therapeutics pipeline.

Wedbush analyst David Nierengarten reiterated an Outperform rating on the stock and maintained a $22 price target, underscoring confidence in Telix’s growth trajectory.

Growth Fueled By Imaging Demand

The move follows a business update highlighting strong momentum in Telix’s Precision Medicine unit, driven by rising adoption of its imaging portfolio.

In its first-quarter 2026 update, Telix said U.S. dose volumes rose 5% quarter over quarter, reflecting sustained demand for key products, including Illuccix and Gozellix.

Revenue Growth And Guidance Reaffirmed

The radiopharmaceuticals company reported first-quarter interim sales of $230 million, up 11% sequentially. Precision Medicine revenue ...